MedTrace Logo

Impact of Specific Oligomeric Supplementation in Oncologic Patients Undergoing Radiotherapy With Malnutrition or at Risk.

NCT07035132 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2025-10-07

No results posted yet for this study

Summary

An observational, prospective, multicenter study to be conducted in 5 hospitals in Spain. Patients with cancer undergoing radiotherapy are malnourished or at risk of malnutrition. Due to the characteristics of their pathology or gastrointestinal disorders, the use of oligomeric nutritional formulas formulated with 100% hydrolyzed whey lactoprotein and a high MCT content is recommended as part of routine clinical practice. Patients will be followed for 12 weeks, with three visits: a baseline visit upon inclusion in the study, after 6 weeks and a final visit 12 weeks after the nutritional treatment starts.

Conditions

  • Malnutrition in Elderly
  • Oncological Patients
  • Digestive Disorders

Interventions

DIETARY_SUPPLEMENT

Oral supplementation with nutritional oligomeric formula

Patients will be supplemented with the specific oligomeric formula (1 or 2 bottles/day, as per investigator's decision) during, at least, the 12 weeks of the study follow-up.

Sponsors & Collaborators

  • Nestlé Health Science Spain

    collaborator INDUSTRY

  • Outcomes'10

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-15
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07035132 on ClinicalTrials.gov